Brett Schnittlich has over thirty years of experience as an entrepreneur, investor, and executive. He has led multiple exits and managed acquisitions across fields as diverse as healthcare, pharmaceutical, advertising, consumer insights, media measurement, and data analytics.
Early in his career, Brett founded Ibis Software, the first clinical trial data capture company. Ibis was acquired by Grey Healthcare, and Brett joined Grey as EVP/Managing Director. Brett brokered the subsequent sale of Ibis to Pharmacentric, rebranding the company as eTrials, prior to joining Torre Lazur/McCann Healthcare as Chief Technology Officer. He then became Managing Partner at Hyphen, an Omnicon Company. After Hyphen, Brett worked with private equity fund Pilot, overseeing, among other M&A deals, the acquisition of OTX (considered by many, the first purely online research company), joining OTX as CTO, and later selling the company to Ipsos. Continuing to innovate in the insights space, Brett served as CTO at Lieberman Research Worldwide (LRW), while serving as a Board Director at Lucid and StatSocial. Brett then joined Lucid full time as President, bringing programmatic marketplace technology to the consumer insights and media measurement industries. Brett led Lucid’s $1.3B sale to CINT AB.
Brett currently sits on the Boards of Directors for Atheneum and dscout, and acts as Board Advisor to Medcase.